^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    ROR1 inhibitor

    Related drugs:
    Apply
    A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies (NCT03088878)
    Phase 1/2
    Oncternal Therapeutics, Inc
    Completed
    Last update posted :
    02/12/2025
    Initiation :
    01/03/2018
    Primary completion :
    09/25/2024
    Completion :
    09/25/2024
    BCL2
    |
    Imbruvica (ibrutinib) • zilovertamab (UC-961)
    A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors (PBL-0405-01) (NCT06273852)
    Phase 1
    Pure Biologics S.A.
    Recruiting
    Last update posted :
    05/17/2024
    Initiation :
    04/29/2024
    Primary completion :
    03/01/2025
    Completion :
    03/01/2025
    ROR1 • TNFA • CASP3 • GZMB • CD86
    Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer (NCT02776917)
    Phase 1
    Barbara Parker, MD
    Completed
    Last update posted :
    04/10/2024
    Initiation :
    08/15/2018
    Primary completion :
    07/13/2021
    Completion :
    02/26/2024
    HER-2 • ER • PGR
    |
    HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • PGR negative
    |
    paclitaxel • zilovertamab (UC-961)
    A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer (GNC-035-103) (NCT05160545)
    Phase 1
    Sichuan Baili Pharmaceutical Co., Ltd.
    Recruiting
    Last update posted :
    01/31/2024
    Initiation :
    11/26/2021
    Primary completion :
    06/01/2024
    Completion :
    06/01/2024
    PD-L1
    |
    nebratamig (GNC-035)
    First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies (NVG111-101) (NCT04763083)
    Phase 1
    NovalGen Ltd.
    Recruiting
    Last update posted :
    07/07/2023
    Initiation :
    05/14/2021
    Primary completion :
    12/01/2023
    Completion :
    12/01/2025
    ROR1
    |
    NVG-111
    A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors (NCT05039931)
    Phase 1
    Sichuan Baili Pharmaceutical Co., Ltd.
    Withdrawn
    Last update posted :
    03/16/2023
    Initiation :
    09/15/2021
    Primary completion :
    06/01/2023
    Completion :
    06/01/2023
    PD-L1
    |
    nebratamig (GNC-035)
    Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961 (NCT02860676)
    Phase 1
    University of California, San Diego
    Completed
    Last update posted :
    03/20/2019
    Initiation :
    11/03/2016
    Primary completion :
    02/27/2018
    Completion :
    05/22/2018
    CD19 • CD5
    |
    zilovertamab (UC-961)
    A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies (CIRLL study) (NCT03420183)
    Phase 1b
    Oncternal Therapeutics, Inc
    Recruiting
    Last update posted :
    02/20/2019
    Initiation :
    02/13/2018
    Primary completion :
    04/01/2019
    Completion :
    12/01/2022
    ROR1
    |
    Imbruvica (ibrutinib) • zilovertamab (UC-961)